Innate Pharma’s Pipeline Progress
Research - In early December we published Mr. Fink’s deep-dive on Innate Pharma (IPH.PA) (IPHYF), explaining why we wanted to own the stock in 2015.
Premium: Read NowzPremium
Conatus’ Recent Data were so Damn Confusing; Sometimes That’s the Best Thing for Investors
Research - Conatus (CNAT) was punished 2 weeks ago with the release of results from 3 phase I/II studies. Thankfully, we suggested taking profit beforehand at +60%.
Premium: Read Now
Tekmira Just Became a Must-Own Stock for 2015
Research - Tekmira Pharmaceuticals (TKMR) is merging with privately held OnCore Biopharma, which develops drugs targeting the Hepatitis B virus (HBV).
Premium: Read Now
Preparing for Conatus’ Upcoming Trial Results
Research - Conatus Pharmaceuticals (CNAT) will release the combined results from 3 phase 1 and 2 studies on Thursday after the bell. CNAT is up 60% from our suggestion to get long the stock this Fall at $6.00.
Premium: Read Now
Cempra Continues to Derisk Lead Asset, Solithromycin
Research - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading
Premium: Read Now
The Easy Money’s Been Made
Research - Our goal was to roll profit from this short-term trade into a small, longer-term position in SRNE, which we plan to let ride through TRIBECA.
Premium: Read Now
HCV Going Through Growing Pains as Achillion Data Hits
Research - Achillion Pharmaceuticals (ACHN) reported anticipated data for its nucleotide inhibitor ACH-3422 this morning alongside data from a phase 2 proxy study.
Premium: Read Now